Silexion Therapeutics Holds Reconvened Shareholder Meeting After Quorum Shortfall

• Silexion Therapeutics shareholders approved a 500,000,000-ordinary-share authorized capital increase at the extraordinary meeting reconvened on October 26, 2026.
• Originally held on October 19, 2026, the meeting also authorized a reverse share split ranging from 1-for-15 to 1-for-25.
• The capital amendment became effective October 26, 2026, increasing authorized ordinary shares from 15,900,000 to 515,900,000.
• The board selected a 1-for-24 ratio for the authorized reverse split, covering issued and outstanding ordinary shares and authorized but unissued ordinary shares.
• The reverse split would increase ordinary shares’ par value from US$0.135 to US$3.24.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004849), on October 26, 2026, and is solely responsible for the information contained therein.